The global pulmonary surfactant market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing incidence of respiratory diseases and rising demand for animal derived pulmonary surfactants.
The synthetic pulmonary surfactants segment accounted for the largest share in the global pulmonary surfactant market in 2018, followed by animal derived pulmonary surfactants and other types. The synthetic segment is expected to maintain its dominance throughout the forecast period owing to its high efficacy and low cost as compared with animal-derived products.
Hospital application accounted for the largest share in the global pulmonary surfactant market in 2018, followed by laboratory application and others (homecare). The hospital application segment is expected to maintain its dominance throughout the forecast period owing to increasing incidence of respiratory diseases globally which will lead to an increase in demand for these products from hospitals.
Some Of The Growth Factors Of This Market:
- Pulmonary surfactant is a substance that reduces surface tension in the lungs and helps to keep airways open.
- Increasing awareness about the benefits of pulmonary surfactants among physicians and patients will also drive market growth.
- Technological advancements in drug delivery systems will also fuel growth.
Industry Growth Insights published a new data on “Pulmonary Surfactant Market”. The research report is titled “Pulmonary Surfactant Market research by Types (Synthetic Pulmonary Surfactants, Animal Derived Surfactants), By Applications (Hospital, laboratory, Others), By Players/Companies Boehringer Ingelheim, AbbVie, Lyomark Pharma, Tekzima (Noargen), ONY Biotech, Abbott, Aviva Systems Biology, LSBio, Biomatik, Biorbyt, Reddot Biotech, XpressBio, Creative Diagnostics, Nanjing Norris Pharm Technology, Windtree Therapeutics”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pulmonary Surfactant Market Research Report
By Type
Synthetic Pulmonary Surfactants, Animal Derived Surfactants
By Application
Hospital, laboratory, Others
By Companies
Boehringer Ingelheim, AbbVie, Lyomark Pharma, Tekzima (Noargen), ONY Biotech, Abbott, Aviva Systems Biology, LSBio, Biomatik, Biorbyt, Reddot Biotech, XpressBio, Creative Diagnostics, Nanjing Norris Pharm Technology, Windtree Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Pulmonary Surfactant Market Report Segments:
The global Pulmonary Surfactant market is segmented on the basis of:
Types
Synthetic Pulmonary Surfactants, Animal Derived Surfactants
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, laboratory, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim
- AbbVie
- Lyomark Pharma
- Tekzima (Noargen)
- ONY Biotech
- Abbott
- Aviva Systems Biology
- LSBio
- Biomatik
- Biorbyt
- Reddot Biotech
- XpressBio
- Creative Diagnostics
- Nanjing Norris Pharm Technology
- Windtree Therapeutics
Highlights of The Pulmonary Surfactant Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Synthetic Pulmonary Surfactants
- Animal Derived Surfactants
- By Application:
- Hospital
- laboratory
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pulmonary Surfactant Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pulmonary surfactant is a type of medication that helps to reduce the amount of fluid in the lungs. It is used to treat conditions such as asthma, emphysema, and chronic bronchitis. Pulmonary surfactant can also be used to prevent lung infections.
Some of the key players operating in the pulmonary surfactant market are Boehringer Ingelheim, AbbVie, Lyomark Pharma, Tekzima (Noargen), ONY Biotech, Abbott, Aviva Systems Biology, LSBio, Biomatik, Biorbyt, Reddot Biotech, XpressBio, Creative Diagnostics, Nanjing Norris Pharm Technology, Windtree Therapeutics.
The pulmonary surfactant market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pulmonary Surfactant Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pulmonary Surfactant Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pulmonary Surfactant Market - Supply Chain
4.5. Global Pulmonary Surfactant Market Forecast
4.5.1. Pulmonary Surfactant Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pulmonary Surfactant Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pulmonary Surfactant Market Absolute $ Opportunity
5. Global Pulmonary Surfactant Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pulmonary Surfactant Market Size and Volume Forecast by Type
5.3.1. Synthetic Pulmonary Surfactants
5.3.2. Animal Derived Surfactants
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pulmonary Surfactant Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pulmonary Surfactant Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. laboratory
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pulmonary Surfactant Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pulmonary Surfactant Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pulmonary Surfactant Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pulmonary Surfactant Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pulmonary Surfactant Demand Share Forecast, 2019-2026
9. North America Pulmonary Surfactant Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pulmonary Surfactant Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pulmonary Surfactant Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. laboratory
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pulmonary Surfactant Market Size and Volume Forecast by Type
9.7.1. Synthetic Pulmonary Surfactants
9.7.2. Animal Derived Surfactants
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pulmonary Surfactant Demand Share Forecast, 2019-2026
10. Latin America Pulmonary Surfactant Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pulmonary Surfactant Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pulmonary Surfactant Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. laboratory
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pulmonary Surfactant Market Size and Volume Forecast by Type
10.7.1. Synthetic Pulmonary Surfactants
10.7.2. Animal Derived Surfactants
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pulmonary Surfactant Demand Share Forecast, 2019-2026
11. Europe Pulmonary Surfactant Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pulmonary Surfactant Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pulmonary Surfactant Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. laboratory
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pulmonary Surfactant Market Size and Volume Forecast by Type
11.7.1. Synthetic Pulmonary Surfactants
11.7.2. Animal Derived Surfactants
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pulmonary Surfactant Demand Share, 2019-2026
12. Asia Pacific Pulmonary Surfactant Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pulmonary Surfactant Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pulmonary Surfactant Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. laboratory
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pulmonary Surfactant Market Size and Volume Forecast by Type
12.7.1. Synthetic Pulmonary Surfactants
12.7.2. Animal Derived Surfactants
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pulmonary Surfactant Demand Share, 2019-2026
13. Middle East & Africa Pulmonary Surfactant Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pulmonary Surfactant Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pulmonary Surfactant Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. laboratory
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pulmonary Surfactant Market Size and Volume Forecast by Type
13.7.1. Synthetic Pulmonary Surfactants
13.7.2. Animal Derived Surfactants
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pulmonary Surfactant Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pulmonary Surfactant Market: Market Share Analysis
14.2. Pulmonary Surfactant Distributors and Customers
14.3. Pulmonary Surfactant Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Boehringer Ingelheim
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AbbVie
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Lyomark Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Tekzima (Noargen)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ONY Biotech
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Abbott
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Aviva Systems Biology
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. LSBio
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biomatik
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Biorbyt
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Reddot Biotech
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. XpressBio
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Creative Diagnostics
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Nanjing Norris Pharm Technology
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Windtree Therapeutics
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
